- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03769506
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will have an Experimental Arm and a Control Arm.
Experimental Arm:
Patients may receive repeated ASP-1929 PIT interventions for up to a maximum of 8 cycles within a period of up to 12 months after randomization until the patient has complete remission, progressive disease that is no longer amendable to study treatment, patient experiences intolerable side effects, or patient discontinues study treatment. Repeat ASP-1929 treatment cycles will be administered no less than 4 weeks from the previous ASP-1929 infusion.
Control Arm:
Patients may be treated with physician's choice standard of care until the patient has progressive disease, patient experiences intolerable side effects, discontinues study treatment, or chooses to withdraw.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Bogdan Veresh, MD
- Phone Number: 858-207-3113
- Email: clinicaltrialinfo@rakuten-med.com
Study Locations
-
-
Gujarat
-
Vadodara, Gujarat, India, 391760
- Recruiting
- Kailash Cancer Hospital and Research Center
-
Contact:
- Yash Damor
- Phone Number: 91-8469554460
-
Principal Investigator:
- Rajesh Kantharia
-
-
Tamilnadu
-
Chennai, Tamilnadu, India, 60036
- Recruiting
- Cancer Institute (W.I.A)
-
Contact:
- S. Deyva Manohari
- Phone Number: 91-8681823668
-
Principal Investigator:
- Venkatraman Radhakrishnan
-
-
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 464-8681
- Active, not recruiting
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- Active, not recruiting
- National Cancer Center Hospital East
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8648
- Active, not recruiting
- Hokkaido University Hospital
-
-
Okayama
-
Okayama-shi, Okayama, Japan, 700-8558
- Active, not recruiting
- Okayama University Hospital
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- Active, not recruiting
- National Cancer Center Hospital
-
-
-
-
-
Taichung, Taiwan, 40705
- Recruiting
- Taichung Veterans General Hospital
-
Principal Investigator:
- Chen-Chi Wang
-
Contact:
- I-Chen Tsai
- Phone Number: 886-911-102-866
-
Taichung, Taiwan, 40705
- Recruiting
- China Medical University Hospital
-
Principal Investigator:
- Chun-Hung Hua
-
Contact:
- Chia Hui Lin
- Phone Number: 886-920-211-277
-
Taoyuan, Taiwan, 333
- Recruiting
- Chang Gung Memorial Hospital
-
Principal Investigator:
- Kai-Ping Chang
-
Contact:
- Lora Chang
- Phone Number: 886-919-977-034
-
-
Taipei
-
Zhongzheng, Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Principal Investigator:
- Pei-Jen Lou
-
Contact:
- Christy Lee
- Phone Number: 88858 886-223-123-456
-
-
-
-
-
Dnipro, Ukraine, 49102
- Active, not recruiting
- City Clinical Hospital #4
-
-
-
-
Florida
-
Tampa, Florida, United States, 33606
- Recruiting
- University of South Florida
-
Principal Investigator:
- Matthew J. Mifsud, MD
-
Contact:
- Tien Nguyen
- Phone Number: 813-844-7745
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Grady Health
-
Principal Investigator:
- Charles E. Moore, MD
-
Contact:
- Frank Akuchie
- Phone Number: 404-942-8907
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Active, not recruiting
- University of Kentucky, Albert B. Chandler Medical Center
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- Recruiting
- William Beaumont Hospital
-
Principal Investigator:
- Jeffrey Hotaling, MD
-
Contact:
- Grace San Agustin
- Phone Number: 248-551-6679
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- University of Pennsylvania
-
Principal Investigator:
- Karthik Rajasekaran, MD
-
Contact:
- Ethan Skinner
- Phone Number: 215-615-1611
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University - Sidney Kimmel Medical College
-
Principal Investigator:
- David Cognetti, MD
-
Contact:
- Camilo Henao
- Phone Number: 215-982-0009
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Active, not recruiting
- Vanderbilt University
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Ann Gillenwater, MD
-
Contact:
- Bridget Reeves
- Phone Number: 713-745-1897
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Overall Inclusion Criteria:
- Have a histologically confirmed locoregional persistent, recurrent or second primary squamous cell carcinoma of the head and neck, not amenable to curative treatment
- Have failed or progressed on or after at least 2 lines of therapy for squamous cell carcinoma of the head and neck.
- Failed or progressed following prior platinum chemotherapy
- Have completed prior curative radiation therapy for treatment of their head and neck region
- Have locoregional head and neck tumor site(s) that are all accessible to illumination
- Have target tumors that are clearly measurable by contract enhanced CT scan
- Have a life expectancy of > 6 months, based on Investigator judgment
- Male participants must agree to use contraception during the treatment period and for at least 6 months after the last ASP-1929 infusion
- Female patients of childbearing potential must not be pregnant or breastfeeding and agree to follow the contraceptive guidance during the treatment period and for at least 6 months after the last dose of trial intervention and must refrain from breastfeeding for at least 2 months after the last ASP-1929 infusion
- Have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
Overall Exclusion Criteria:
- Have a history of significant (>= Grade 3) cetuximab infusion reactions
- Have been treated with prior systematic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of trial Day 1 or not recovered from adverse events due to a previously administered agent
- Have been treated with an anticancer monoclonal antibody therapy within 4 weeks of trial Day 1 or have not recovered from adverse events due to previously administered agent
- Have been treated with an investigational agent or intervention within 4 weeks of trial Day 1 or have not recovered from adverse events, due to previously administered agent or intervention
- Have a present history of distant metastatic disease (M1)
- Have an active undergoing treatment or have a diagnosis of an active cancer other than nonmelanoma skin cancer or HNSCC
- Have a tumor in enhanced CT or MRI scan invading a major blood vessel, unless the vessel has been embolized, stented or surgically ligated to prevent potential bleeding from a blood vessel
- Have impaired hepatic function
- Have impaired renal function
- Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with trial requirements
- Have been previously treated or randomized to any trial using ASP-1929 or RM-1929 PIT as the study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Physician's Choice SOC
docetaxel, cetuximab, methotrexate, paclitaxel
|
docetaxel, cetuximab, methotrexate, paclitaxel
|
Experimental: ASP-1929 Photoimmunotherapy
Use of ASP-1929 Photoimmunotherapy
|
Use of ASP-1929 PIT therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: 24 months
|
PFS, defined as the time from randomization to the first occurrence of disease progression (PD), as determined by the investigator according to RECIST 1.1, or death from any cause, whichever one occurs first.
|
24 months
|
Overall Survival (OS)
Time Frame: 24 months
|
OS, defined by the time interval between the patient randomization and death due to any cause.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response (CR)
Time Frame: 24 months
|
CR, defined as disappearance of all target lesions, as determined by Central Radiographic Review according to RECIST 1.1 criteria with modifications.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10mm.
|
24 months
|
Complete Response by Biopsy (CRb)
Time Frame: 24 months
|
CR by histopathologic biopsy of target tumor(s) and a repeat confirmatory histopathologic CR biopsy at least 3 months after initial CR histopathologic biopsy of the target tumor(s) for patients that do not demonstrate a CR by RECIST 1.1 with modifications.
CR: Disappearance of all target lesions.
|
24 months
|
Duration of Response (DoR)
Time Frame: 24 months
|
DoR, defined as the time from first objective response (CR or PR) to the date of the first documented tumor progression, as determined by Central Radiographic Review according to RECIST 1.1 criteria with modifications or date of death due to any cause, whichever occurs first.
CR: Disappearance of all target lesions.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
24 months
|
Event-Free Survival (EFS)
Time Frame: 24 months
|
EFS, defined as the time interval from randomization to a >20% increase in tumor size from baseline (defined as CT scan at screening) by RECIST 1.1 with modifications, development of new locoregional disease, distant metastatic disease, or death.
|
24 months
|
Eastern Cooperative Oncology Group (ECOG) performance status
Time Frame: 24 months
|
24 months
|
|
Quality of Life (QoL) assessment - EQ 5D-5L
Time Frame: 24 months
|
Change from baseline in EuroQol 5-Dimension 5-Level (EQ 5D-5L) Questionnaire.
EQ-5D-5L is a 5-dimension (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) questionnaire developed to assess the patient-generated health state index score from the societal perspective and subjective perceived health.
For each dimension, levels of perceived problems are coded from level 1 (minimum) to level 5 (maximum): no problems (1), slight problems (2), moderate problems (3), severe problems (4), and extreme problems/inability (5).
A second part of the questionnaire provides a visual analogue scale (VAS) for individually perceived health from 0 to 100 (corresponding to the worst to the best imaginable health).
|
24 months
|
Population Pharmacokinetics (PK) of ASP-1929
Time Frame: 12 months
|
Estimate covariate effects of ASP-1929 PK through compartmental PK modeling.
|
12 months
|
Presence of Anti-Drug Antibodies (ADA)
Time Frame: 24 months
|
24 months
|
|
Objective Response Rate (ORR)
Time Frame: 24 months
|
ORR, defined by the percentage of patients with the best overall response of complete response (CR) or partial response (PR) by RECIST 1.1.
CR: Disappearance of all target lesions.
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
|
24 months
|
Quality of Life (QoL) assessment - EORTC QLQ-C30
Time Frame: 24 months
|
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30).
EORTC QLQ-C30 is a 30-item questionnaire developed to assess QoL of head and neck cancer participants and consists of five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease.
It has four-point scales for the first 28 items.
The minimum value is 1 and maximum value is 4. Higher scores mean a worse outcome.
Overall health was evaluated as a 7-point response scale as the other two questions in that scale.
The minimum value is 1 and maximum value is 7. Higher scores mean a better outcome.
|
24 months
|
Quality of Life (QoL) assessment - EORTC QLQ H&N 35
Time Frame: 24 months
|
Change from baseline in EORTC head and neck specific module (EORTC QLQ H&N 35).
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multiple-item scales that assess the symptom of pain, swallowing, senses (taste/smell), speech, social eating, social contact and sexuality.
Also, six single-item scales are included to survey the presence of symptomatic problems associated with teeth, mouth=opening, dry mouth, sticky saliva, coughing, and feeling ill.
The minimum value is 1 and maximum value is 4. It has 2-point scales for the last 5 items.
The minimum value is 1 and maximum value is 2. For all items and scales, high scores indicate more problems.
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Naomi Schechter, Rakuten Medical
Publications and helpful links
General Publications
- Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2021 Jan 1;33(1):7-15. doi: 10.1093/intimm/dxaa037.
- Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASP-1929-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
-
Radboud University Medical CenterUnknown
Clinical Trials on ASP-1929 Photoimmunotherapy
-
Rakuten Medical, Inc.National Cancer Institute (NCI); Shimadzu CorporationRecruitingHead and Neck Cancer | Squamous Cell Carcinoma of Head and NeckUnited States
-
Rakuten Medical, Inc.Active, not recruiting
-
Rakuten Medical, Inc.Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell CarcinomaUnited States
-
Northwestern UniversityTerminated
-
Medical University of ViennaUnknown
-
Abu Dhabi Stem Cells CenterRecruitingMultiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary ProgressiveUnited Arab Emirates
-
University of ChicagoAsphelia PharmaceuticalsCompletedAllergic RhinitisUnited States
-
ASP HealthMayo ClinicNot yet recruitingLung Diseases | Lung Cancer
-
University of TorontoSinai Health SystemUnknownSore Throat | Acute Rhinosinusitis | Acute Bronchitis | Acute CystitisCanada
-
Rakuten Medical, Inc.CompletedRecurrent Head and Neck CancerUnited States